BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

266 related articles for article (PubMed ID: 24768443)

  • 1. Axillary dissection versus no axillary dissection in older T1N0 breast cancer patients: 15-year results of trial and out-trial patients.
    Martelli G; Boracchi P; Orenti A; Lozza L; Maugeri I; Vetrella G; Agresti R
    Eur J Surg Oncol; 2014 Jul; 40(7):805-12. PubMed ID: 24768443
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial comparing axillary dissection to no axillary dissection in older patients with T1N0 breast cancer: results after 5 years of follow-up.
    Martelli G; Boracchi P; De Palo M; Pilotti S; Oriana S; Zucali R; Daidone MG; De Palo G
    Ann Surg; 2005 Jul; 242(1):1-6; discussion 7-9. PubMed ID: 15973094
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Axillary dissection versus no axillary dissection in older patients with T1N0 breast cancer: 15-year results of a randomized controlled trial.
    Martelli G; Boracchi P; Ardoino I; Lozza L; Bohm S; Vetrella G; Agresti R
    Ann Surg; 2012 Dec; 256(6):920-4. PubMed ID: 23154393
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Axillary lymph node dissection versus no dissection in patients with T1N0 breast cancer: a randomized clinical trial (INT09/98).
    Agresti R; Martelli G; Sandri M; Tagliabue E; Carcangiu ML; Maugeri I; Pellitteri C; Ferraris C; Capri G; Moliterni A; Bianchi G; Mariani G; Trecate G; Lozza L; Langer M; Rampa M; Gennaro M; Greco M; Menard S; Pierotti MA
    Cancer; 2014 Mar; 120(6):885-93. PubMed ID: 24323615
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Completion axillary lymph node dissection not required for regional control in patients with breast cancer who have micrometastases in a sentinel node.
    Yegiyants S; Romero LM; Haigh PI; DiFronzo LA
    Arch Surg; 2010 Jun; 145(6):564-9. PubMed ID: 20566977
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High Ki67 predicts unfavourable outcomes in early breast cancer patients with a clinically clear axilla who do not receive axillary dissection or axillary radiotherapy.
    Zurrida S; Bagnardi V; Curigliano G; Mastropasqua MG; Orecchia R; Disalvatore D; Greco M; Cataliotti L; D'Aiuto G; Talakhadze N; Goldhirsch A; Viale G
    Eur J Cancer; 2013 Oct; 49(15):3083-92. PubMed ID: 23777741
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Phase III randomized equivalence trial of early breast cancer treatments with or without axillary clearance in post-menopausal patients results after 5 years of follow-up.
    Avril A; Le Bouëdec G; Lorimier G; Classe JM; Tunon-de-Lara C; Giard S; MacGrogan G; Debled M; Mathoulin-Pélissier S; Mauriac L;
    Eur J Surg Oncol; 2011 Jul; 37(7):563-70. PubMed ID: 21665421
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sentinel node biopsy after neoadjuvant treatment in breast cancer: Five-year follow-up of patients with clinically node-negative or node-positive disease before treatment.
    Galimberti V; Ribeiro Fontana SK; Maisonneuve P; Steccanella F; Vento AR; Intra M; Naninato P; Caldarella P; Iorfida M; Colleoni M; Viale G; Grana CM; Rotmensz N; Luini A
    Eur J Surg Oncol; 2016 Mar; 42(3):361-8. PubMed ID: 26746091
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Positive axillary sentinel lymph node: is axillary dissection always necessary?
    Galimberti V; Chifu C; Rodriguez Perez S; Veronesi P; Intra M; Botteri E; Mastropasqua M; Colleoni M; Luini A; Veronesi U
    Breast; 2011 Oct; 20 Suppl 3():S96-8. PubMed ID: 22015302
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Is regional nodes radiotherapy an alternative to surgery?
    Offersen BV; Nielsen HM; Overgaard M; Overgaard J
    Breast; 2013 Aug; 22 Suppl 2():S118-28. PubMed ID: 24074772
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Management of the axilla in breast cancer: evidences and unresolved issues].
    Fodor J; Polgár C; Péley G; Németh G
    Orv Hetil; 2001 Sep; 142(36):1941-50. PubMed ID: 11680099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elderly breast cancer patients treated by conservative surgery alone plus adjuvant tamoxifen: fifteen-year results of a prospective study.
    Martelli G; Miceli R; Costa A; Coradini D; Zurrida S; Piromalli D; Vetrella G; Greco M
    Cancer; 2008 Feb; 112(3):481-8. PubMed ID: 18098268
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Disease-free survival advantage of weekly epirubicin plus tamoxifen versus tamoxifen alone as adjuvant treatment of operable, node-positive, elderly breast cancer patients: 6-year follow-up results of the French adjuvant study group 08 trial.
    Fargeot P; Bonneterre J; Roché H; Lortholary A; Campone M; Van Praagh I; Monnier A; Namer M; Schraub S; Barats JC; Guastalla JP; Goudier MJ; Chapelle-Marcillac I
    J Clin Oncol; 2004 Dec; 22(23):4622-30. PubMed ID: 15505276
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term follow-up of 5262 breast cancer patients with negative sentinel node and no axillary dissection confirms low rate of axillary disease.
    Galimberti V; Manika A; Maisonneuve P; Corso G; Salazar Moltrasio L; Intra M; Gentilini O; Veronesi P; Pagani G; Rossi E; Bottiglieri L; Viale G; Rotmensz N; De Cicco C; Grana CM; Sangalli C; Luini A
    Eur J Surg Oncol; 2014 Oct; 40(10):1203-8. PubMed ID: 25186914
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sentinel lymph node biopsy is a reliable method for lymph node evaluation in neoadjuvant chemotherapy-treated patients with breast cancer.
    Koslow SB; Eisenberg RE; Qiu Q; Chen Z; Swistel A; Shin SJ
    Am Surg; 2014 Feb; 80(2):171-7. PubMed ID: 24480218
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of axillary reverse mapping related factors on lymphedema in breast cancer patients.
    Ikeda K; Ogawa Y; Kajino C; Deguchi S; Kurihara S; Tashima T; Goto W; Nishiguchi Y; Tokunaga S; Fukushima H; Inoue T
    Eur J Surg Oncol; 2014 Jul; 40(7):818-23. PubMed ID: 24768416
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized trial comparing axillary clearance versus no axillary clearance in older patients with breast cancer: first results of International Breast Cancer Study Group Trial 10-93.
    ; Rudenstam CM; Zahrieh D; Forbes JF; Crivellari D; Holmberg SB; Rey P; Dent D; Campbell I; Bernhard J; Price KN; Castiglione-Gertsch M; Goldhirsch A; Gelber RD; Coates AS
    J Clin Oncol; 2006 Jan; 24(3):337-44. PubMed ID: 16344321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Favorable outcome of secondary axillary dissection in breast cancer patients with axillary nodal relapse.
    Shen SC; Liao CH; Lo YF; Tsai HP; Kuo WL; Yu CC; Chao TC; Chen MF; Chang HK; Lin YC; Shen WC; Ueng SH; Lee LY; Hsueh S; Huang YT; Chen SC
    Ann Surg Oncol; 2012 Apr; 19(4):1122-8. PubMed ID: 21969085
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Therapeutic options and results for the management of minimally invasive carcinoma of the breast: influence of axillary dissection for treatment of T1a and T1b lesions.
    White RE; Vezeridis MP; Konstadoulakis M; Cole BF; Wanebo HJ; Bland KI
    J Am Coll Surg; 1996 Dec; 183(6):575-82. PubMed ID: 8957459
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intraoperative sentinel node biopsy by one-step nucleic acid amplification (OSNA) avoids axillary lymphadenectomy in women with breast cancer treated with neoadjuvant chemotherapy.
    Navarro-Cecilia J; Dueñas-Rodríguez B; Luque-López C; Ramírez-Expósito MJ; Martínez-Ferrol J; Ruíz-Mateas A; Ureña C; Carrera-González MP; Mayas MD; Martínez-Martos JM
    Eur J Surg Oncol; 2013 Aug; 39(8):873-9. PubMed ID: 23711734
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.